Liver Fibrosis Pipeline Analysis Demonstrates Novel 30+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

DelveInsight's, "Liver Fibrosis Pipeline Insight 2023" report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in the Liver Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Liver Cirrhosis Emerging Drugs, the Liver Cirrhosis pipeline analysis report provides a 360° view of the Liver Cirrhosis pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Liver Cirrhosis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

In the Liver Cirrhosis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Liver Cirrhosis clinical trials studies, Liver Cirrhosis NDA approvals (if any), and product development activities comprising the technology, Liver Cirrhosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key takeaways from the Liver Cirrhosis Pipeline Report

• Over 20+ Liver Cirrhosis companies are evaluating 30+ Liver Cirrhosis pipeline therapies in various stages of development, and their anticipated acceptance in the Liver Cirrhosis market would significantly increase market revenue.

• The leading Liver Cirrhosis Companies include Inventiva Pharma, Galmed Pharmaceuticals, Clovis Oncology, Novartis, Hepion Pharmaceuticals, Inc., Kowa Pharmaceutical, Zedira GmbH, Pfizer, Beijing Continent Pharmaceutical Co, Ltd., Zydus Therapeutics Inc., TaiwanJ Pharmaceuticals Co., Ltd, HEC Pharm, Genoscience, Ark Biosciences, and others.

• Promising Liver Cirrhosis Pipeline Therapies includes IDN-6556, ADSCs, NGM282, Rifaximin SSD 40 mg IR tablet, Livercellgram, INT-747, Obeticholic Acid (OCA), and others.

• The Liver Cirrhosis Companies and academics that are working to assess challenges and seek opportunities that could influence Liver Cirrhosis R&D. The Liver Cirrhosis pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

Request a sample and discover the recent breakthroughs happening in the Liver Fibrosis Pipeline landscape @ Liver Fibrosis Pipeline Outlook Report- https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Fibrosis Overview
Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation. Hepatic fibrosis is the result of the wound-healing response of the liver to repeated injury.

Recent Developmental Activities in the Liver Cirrhosis Treatment Landscape

• Seladelpar (MBX-8025) is a potent, selective, orally active peroxisome proliferator-activated receptor δ (PPARδ) agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC). It has received Breakthrough Therapy Designation (FDA) and PRIME status (EMEA); Orphan Drug Designation in U.S. and Europe. Backed by an extensive body of clinical evidence and global patient experience through its Phase 2 and Phase 3 (ENHANCE) studies of seladelpar in Primary Biliary Cholangitis (PBC).

For further information, refer to the detailed Liver Fibrosis Drugs Launch, Liver Fibrosis Developmental Activities, and Liver Fibrosis News, click here for Liver Fibrosis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Liver Fibrosis Emerging Drugs Profile

• Lanifibranor: Inventiva Pharma
Lanifibranor is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory as well as beneficial metabolic changes in the body by activating each of the three PPAR isoforms, known as PPARα, PPARδ and PPARɣ. PPARs are ligand-activated transcription factors belonging to the nuclear hormone receptor family that regulate the expression of genes. PPARs play essential roles in the regulation of cellular differentiation, development and tumorigenesis. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment in patients with NASH and liver fibrosis stage 2 or 3.

• Aramchol meglumine: Galmed Pharmaceuticals
Aramchol (arachidyl amido cholanoic acid) is a first-in-class, novel synthetic small molecule, a conjugate of cholic acid and arachidic acid, liver targeted SCD1 modulator, developed as an oral therapy for the treatment of NASH (nonalcoholic steatohepatitis) and fibrosis. Aramchol targets stearoyl-CoA desaturase 1 (SCD1), the rate-limiting step in the synthesis of monounsaturated fatty acids (MUFAs), the major fatty acid of triglycerides, cholesteryl esters, and membrane phospholipids. Aramchol also increases metabolite flux through the trans-sulfuration pathway, leading to a rise in glutathione (GSH) and the GSH/glutathione disulfide (GSSG) ratio, which preserve cellular antioxidant levels and intracellular redox status. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Liver Fibrosis.

• FAP-2286: Clovis Oncology
FAP-2286 is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP). FAP-2286 consists of two functional elements; a targeting peptide that binds to FAP and a site that can be used to attach radioactive isotopes for imaging and therapeutic use. FAP is highly expressed in many epithelial cancers, including more than 90 percent of breast, lung, colorectal and pancreatic carcinomas. Clovis holds U.S. and global rights for FAP-2286 excluding Europe, Russia, Turkey, and Israel. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Liver Fibrosis.

Liver Fibrosis Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Liver Fibrosis. The companies which have their Liver Fibrosis drug candidates in the most advanced stage, i.e. Phase III include, Inventiva Pharma.

Find out more about the Liver Fibrosis Pipeline Segmentation, Therapeutics Assessment, and Liver Fibrosis Emerging Drugs @ Liver Fibrosis Treatment Landscape- https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Liver Fibrosis Pipeline Report

• Coverage- Global

• Liver Cirrhosis Companies- Inventiva Pharma, Galmed Pharmaceuticals, Clovis Oncology, Novartis, Hepion Pharmaceuticals, Inc., Kowa Pharmaceutical, Zedira GmbH, Pfizer, Beijing Continent Pharmaceutical Co, Ltd., Zydus Therapeutics Inc., TaiwanJ Pharmaceuticals Co., Ltd, HEC Pharm, Genoscience, Ark Biosciences, and others

• Liver Cirrhosis Pipeline Therapies- IDN-6556, ADSCs, NGM282, Rifaximin SSD 40 mg IR tablet, Livercellgram, INT-747, Obeticholic Acid (OCA), and others.

• Liver Cirrhosis Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Liver Fibrosis Pipeline Companies and Therapies, click here @ Liver Fibrosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Liver Cirrhosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Liver Cirrhosis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Seladelpar: CymaBay Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. AV 1142742: Active Biotech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. ADR-001: Rohto Pharmaceutical
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. ZG 5216: Suzhou Zelgen Biopharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Liver Cirrhosis Key Companies
21. Liver Cirrhosis Key Products
22. Liver Cirrhosis- Unmet Needs
23. Liver Cirrhosis- Market Drivers and Barriers
24. Liver Cirrhosis- Future Perspectives and Conclusion
25. Liver Cirrhosis Analyst Views
26. Liver Cirrhosis Key Companies
27. Appendix

Got Queries? Find out the related information on Liver Fibrosis Mergers and acquisitions, Liver Fibrosis Licensing Activities @ Liver Fibrosis Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/liver-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.